老年性黄斑变性是西方国家55岁以上人群的主要致盲原因。在我国该病的发病率也逐年升高。现有的治疗方式存在一定局限性。近年药物治疗老年性黄斑变性越来越受到重视。本文对目前已应用于临床以及即将应用于临床的药物,包括Macugen、Lucentis、曲安奈德、Retaane、Evi-zon、Avastin等的研究现状作一综述。 Age-related macular degeneration is the leading cause of blindness in people over the age of 55 in Western countries. In our country the incidence of the disease also increased year by year. The existing treatment has some limitations. In recent years, drug treatment of AMD has attracted more and more attention. This review summarizes the research status of the drugs currently used clinically and to be applied clinically, including Macugen, Lucentis, Triamcinolone acetonide, Retaane, Evi-zon and Avastin.